UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 9, 2010
(Exact Name of Registrant as Specified in Charter)
| | | | | |
|
| Delaware | | 000-31191 | | 04-3324394 |
| | | | | |
(State or Other Jurisdiction
of Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
| | | |
|
8 Sylvan Way
Parsippany, New Jersey | | 07054 |
| | | |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code:(973) 290-6000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On July 8, 2010, The Medicines Company (the “Company”) received a Paragraph IV Certification notice letter from Hospira, Inc. (“Hospira”) notifying the Company that Hospira has submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration for approval to market a generic version of Angiomax. The Certification notice letter relates to U.S. Patent Nos. 7,582,727 and 7,598,343, which cover a more consistent and improved Angiomax drug product and the processes by which it is made. The Company intends to vigorously defend its intellectual property rights.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | THE MEDICINES COMPANY
| |
| Date: July 9, 2010 | By: | /s/ Paul M. Antinori | |
| | | Paul M. Antinori | |
| | | Senior Vice President and General Counsel | |
| |
